Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Marie Skłodowska-Curie Action · Running

EngineeringSARCOMAs Building models of fusion-driven sarcomas via cell fate engineering

Coordinator
St. Anna Kinderkrebsforschung GmbH, Austria
Runs
1 May 2024 to 30 April 2026
Status
Running
EU funding
€184k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101149215

What the project is doing

In the project's own words, from its summary on CORDIS.

One of the unsolved problems in cancer biology is why and how do certain oncogenic driver genes promote cancer in one cellular context but not in another. This project focuses on fusion oncogenes relevant to sarcomas, which are sarcoma type-specific and tumorigenic only in certain cellular states. By combining cell fate engineering of human pluripotent stem cells (hPSCs) with forced expression of sarcoma-linked fusions, I will systematically probe the cellular contexts and molecular mechanisms of fusion-driven sarcomagenesis, with the prospect of building novel disease models that could be used for testing new therapies.

I hypothesize that fusion-driven sarcomas emerge from the combination of an oncogenic fusion protein and a cell-of-origin that is defined by a characteristic state prone to transformation. I will investigate the interplay between a specific cellular context and the activity of a particular fusion and whether a permissive cellular context is sufficient for fusions to execute their tumorigenic programs. I will pursue a build it to understand it approach and construct sarcoma models starting from hPSCs inducible for the expression of five sarcoma-linked fusions respectively.

I will validate these models against single-cell and spatial maps of sarcoma tumors available in the host lab. I will exploit two complementary approaches for creating cells permissive to different fusion oncogenes: i. Programmed differentiation of hPSCs with precise molecular intervention in vitro (Objective 1); ii. Genetically engineered teratomas that could allow for full in vivo modeling of sarcomas (Objective 2).

Alignment with the call: Innovative, collaborative, multidisciplinary project expected to qualify the applicant for a principal investigator position and an ERC starting grant. Candidate is promising early career female scientist moving from Italy to Austria. The candidate will bring her knowledge and new possible collaborations to the host lab.

Topics

Who is involved

OrganisationCityCountryRole
St. Anna Kinderkrebsforschung GmbHWienAustriaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI